ABCSG R07 Rectal Cancer Registry (ABCSG R07 RCR)
ABCSG R07 Rectal Cancer Registry (RCR) - Multicenter Retrospective and Prospective Analysis of Patients With Localized, Non-metastatic Rectal Cancer in Austria
In Austria, patients with rectal cancer that has not spread to other parts of the body are typically treated with either total neoadjuvant therapy (TNT) or immunotherapy, depending on their microsatellite status (DNA repair capacity).
However, treatment can vary considerably between hospitals in Austria. These differences may include the type and duration of treatment, as well as the active ingredients used. There are currently no clear recommendations on which exact treatment is best for each specific case.
The aim of this observational study is to collect information on the different treatments used in Austria for patients with localized rectal cancer and to document the outcomes of these treatments.
Only information and samples collected as part of the patients' routine care will be used for the study. Participation in the study will not change or affect the treatment chosen by the treating physician.
Studie Overzicht
Toestand
Gedetailleerde beschrijving
The purpose of this observational study is to establish a registry for locally advanced rectal adenocarcinoma. This registry will document the treatment regimens of participants receiving "total neoadjuvant therapy (TNT)" as well as those with dMMR/MSI-H disease.
The ABCSG R07 Rectal Cancer Registry (RCR) study will provide real-world data that reflect the current therapeutic landscape for participants. Participants who are either treated with "total neoadjuvant therapy (TNT)" or those with dMMR/ MSI-H disease, as well as their response to the respective standard therapy, will be documented.
"Total neoadjuvant therapy (TNT)" is the preferred treatment option for locally advanced rectal adenocarcinoma; however, treatment is carried out according to a different TNT protocol at each hospital or institute.
Since the observational study does not interfere with the course of treatment, neither additional health risks nor any individual benefit from participation in the non-interventional study is to be expected.
This study is being conducted at approx. 6 study sites in Austria, and a total of about 600 participants (retrospective and prospective) will take part. The treating physician selects the treatment/therapy that she/he considers most appropriate for the participant. In the retrospective part participants with localized, non-metastatic rectal cancer treated with total neoadjuvant therapy or participants with dMMR/MSI-H status irrespective of treatment between June 2020 (or June 2005 for dMMR/MSI-H cohort,) and start of this non-interventional study will be enrolled.
In the prospective part participants with localized, non-metastatic rectal cancer treated with total neoadjuvant therapy or participants with dMMR/MSI-H status irrespective of treatment between start of this non-interventional study and three years thereafter will be enrolled.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Miriam Muehlburger, MSc
- Telefoonnummer: +43 1 4089230
- E-mail: miriam.muehlburger@abcsg.at
Studie Locaties
-
-
State of Salzburg
-
Salzburg, State of Salzburg, Oostenrijk, 5020
- LKH Salzburg-PMU, Univ. Klinik f. Innere Med III
-
Contact:
- Lukas Weiss, MD, Prof.
- Telefoonnummer: 25804 +4357255
- E-mail: lu.weiss@salk.at
-
Hoofdonderzoeker:
- Lukas Weiss, MD, Prof.
-
-
Upper Austria
-
Linz, Upper Austria, Oostenrijk, 4020
- Kepler Universitätsklinikum Linz
-
Contact:
- Gudrun Piringer, MD, MSc
- Telefoonnummer: +435768082
- E-mail: gudrun.piringer@kepleruniklinikum.at
-
Hoofdonderzoeker:
- Gudrun Piringer, MD, MSc
-
Linz, Upper Austria, Oostenrijk, 4010
- Ordensklinikum Linz - BHS
-
Contact:
- Holger Rumpold, MD, Head
- Telefoonnummer: 4230 +43-732-7677
- E-mail: holger.rumpold@bhs.at
-
Hoofdonderzoeker:
- Holger Rumpold, MD, Head
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Female and male participants with age >= 18 years
- Signed informed consent obtained prior to registration of the participant.
- Localized rectal cancer treated with TNT or localized, non-metastatic dMMR/MSI-H rectal cancer, irrespective of treatment
Exclusion Criteria:
- Distant metastases at primary diagnosis
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
|---|
|
Retrospective part
Participants treated between June 2020 and study start.
For dMMR/MSI-H cohort: treated between June 2005 until study start
|
|
Prospective part
Participants treated between study start and three years after study start
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Treatment Responses (clinical standard therapy)
Tijdsspanne: At the time of surgery
|
Recording of treatment responses according to clinical standard therapy.
|
At the time of surgery
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Proportion of different TNT concepts used
Tijdsspanne: From therapy start to Surgery
|
Treatment details
|
From therapy start to Surgery
|
|
Proportion of participants using immunotherapy
Tijdsspanne: From therapy start to Surgery
|
From therapy start to Surgery
|
|
|
Proportion of participants using watch & wait therapy
Tijdsspanne: At surgery visit
|
At surgery visit
|
|
|
Proportion of the surgical techniques used
Tijdsspanne: At surgery
|
At surgery
|
|
|
Proportion of locoregional recurrences
Tijdsspanne: From therapy start until 3 years from re-staging or end of primary treatment
|
From therapy start until 3 years from re-staging or end of primary treatment
|
|
|
Proportion of the participants with distant metastases
Tijdsspanne: From therapy start until 3 years from re-staging or end of primary treatment
|
From therapy start until 3 years from re-staging or end of primary treatment
|
|
|
Event-free survival (EFS)
Tijdsspanne: From therapy start until 3 years from re-staging or end of primary treatment
|
EFS includes locoregional event, distant metastasis and death
|
From therapy start until 3 years from re-staging or end of primary treatment
|
|
TME-free survival in watch & wait group
Tijdsspanne: From therapy start until 3 years from re-staging or end of primary treatment
|
From therapy start until 3 years from re-staging or end of primary treatment
|
|
|
Overall survival (OS)
Tijdsspanne: From therapy start until 3 years from re-staging or end of primary treatment
|
From therapy start until 3 years from re-staging or end of primary treatment
|
|
|
Locoregional event-free survival (LREFS)
Tijdsspanne: From therapy start until 3 years from re-staging or end of primary treatment
|
locoregional progression, recurrence, regrowth or death
|
From therapy start until 3 years from re-staging or end of primary treatment
|
|
Distant metastasis-free survival (DMFS)
Tijdsspanne: From therapy start until 3 years from re-staging or end of primary treatment
|
From therapy start until 3 years from re-staging or end of primary treatment
|
|
|
Charlson Comorbidity Index (CCI) Score prior to any treatment start
Tijdsspanne: Baseline
|
Baseline
|
|
|
ECOG performance status at diagnosis
Tijdsspanne: Diagnosis
|
Diagnosis
|
|
|
Proportion of resection rates
Tijdsspanne: Surgery
|
Surgery
|
|
|
Treatment adherence
Tijdsspanne: From therapy start until surgery
|
From therapy start until surgery
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Studie stoel: Falk Roeder, Prof, MD, Paracelsius Medical University Salzburg
- Studie stoel: Gudrun Piringer, MD, MSc, Johannes Kepler University Linz
- Studie stoel: Lukas Weiss, Prof, MD, Paracelsius Medical University Salzburg
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Darmziekten
- Neoplasmata per histologisch type
- Gastro-intestinale neoplasmata
- Neoplasmata van het spijsverteringsstelsel
- Ziekten van het spijsverteringsstelsel
- Gastro-intestinale aandoeningen
- Colorectale neoplasmata
- Intestinale neoplasmata
- Rectale ziekten
- Neoplasmata, glandulair en epitheel
- Carcinoom
- Neoplasmata
- Rectale neoplasmata
- Adenocarcinoom
- Turcot -syndroom
Andere studie-ID-nummers
- ABCSG R07
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Key-coded personal information from this study may also be used for future ((non-)commercial, (inter-)national) scientific research projects & statistics, provided the respective project is conducted in compliance with accepted standards of ethical principles; the responsible researcher(s)/statistician(s) has/have no legal means to de-identify any key-coded personal information.
Data will be shared with other collaborating academic groups/people & companies who work with the Sponsors, including but not limited to ECs, ABCSG (holder of clin. database) and will be used for study purposes mentioned in protocol & future scientific research projects, if agreed by the participant.
Any data transfer will comply with respective applicable data law/regulations. The use of data must be defined in advance in a project description & SAP, approved by ABCSG Board/Committee and will be transferred acc. with resp. Data Transfer Agreement.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .